A survey to determine the views of renal transplant patients on generic substitution in the UK

Transplant International

Volumn 24, Issue 8, 2011, Pages 770-779

  Al Ameri, Mubarak N ^a   Whittaker, Clare ^b   Tucker, Arthur ^a   Yaqoob, Magdi ^a,b   Johnston, Atholl ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

clinical outcomes; generic medicines; generic substitution; patients' opinions; professionals' roles on generic substitution

Indexed keywords

CYCLOSPORIN A; GENERIC DRUG;

ADULT; AGED; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG SUBSTITUTION; FEMALE; HOSPITAL ADMISSION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; UNITED KINGDOM;

ADULT; AGED; ATTITUDE TO HEALTH; CYCLOSPORINE; DRUG SUBSTITUTION; DRUGS, GENERIC; FEMALE; GREAT BRITAIN; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; QUESTIONNAIRES;

EID: 79960150484     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01268.x     Document Type: Review

References (47)

1. Bloor K, Freemantle N,. Lessons from international experience in controlling pharmaceutical expenditure. II: influencing doctors. BMJ 1996; 312: 1525.
2. Department of Health (DH). Consultation on the proposals to implement 'Generic Substitution' in primary care, 2010. Available at: (cited January 26, 2010).
3. Haas JS,. Potential savings from substitution generic drugs for brand drugs: Medical Expenditures Panel Survey 1997-2000. Ann Intern Med 2005; 142: 891.
4. Tilson L, Bennett K, Barry M,. The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland. Eur J Health Econ 2005; 6: 267.
5. Andersson K, Sonesson C, Petzold M, Carlsten A, Lonnroth K,. What are the obstacles to generic substitution?. An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden Pharmacoepidemiol Drug Saf 2005; 14: 341.
6. Sagardui-Villamor JK, Lacalle Rodriguez-Labajo M, Casado-Buendia S,. Substitution of generic for brand medicines in primary care. Factors associated to refuse the change. Aten Primaria 2005; 9: 489.
7. Igoe G,. Generic utilisation on the general medical services scheme in 2001. Ir Med J 2003; 96: 315.
8. Kjoenniksen I, Lindbaek M, Granas AG,. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006; 28: 284.
9. Department of Health (DH) Press Release. No plans to implement generic substitution of medicines, 2010. Available at: http://tinyurl.com/4qpuvwx (cited March 2, 2011).
10. Suh DC,. Trends of generic substitution in community pharmacies. Pharm World Sci 1999; 21: 260.
11. Kereiakes DJ, Willerson JT,. Therapeutic substitution: guilty until proven innocent. Circulation 2003; 108: 2611.
12. Phillips B, Roberts C, Rudolph AE, Morant S, Aziz F, O'Regan CP,. Switching statins: the impact on patient outcomes. Br J Cardiol 2007; 14: 280.
13. Snow V, Weiss KB, Mottur-Pilson C,. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003; 138: 587.
14. Himmel W, Simmenroth-Nayda A, Niebling W, et al. What do primary care patients think about generic drugs. Int J Clin Pharmacol Ther 2005; 43: 472.
15. Pocock SJ,. The pros and cons of noninferiority trials. Fundam Clin Pharmacol 2003; 17: 483.
16. Garattini S, Bertele V,. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 2007; 370: 1875.
17. Alameri M, Epstein M, Johnston A,. Generic and therapeutic substitutions: are they always ethical in their own terms? Pharm World Sci 2010; 32: 691.
18. Duerden MG, Hughes DA,. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol 2010; 70: 335.
19. McGettigan P, McManus J, O'Shea B, Chan R, Feely J,. Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: prescribers' concerns. Ir Med J 1997; 90: 146.
20. National Health Service. Prescriptions dispensed in the community statistics for 1996 to 2006: England The NHS Information Centre, 2006. Available at: http://tinyurl.com/d8yux2 (cited June 11, 2009).
21. Dombrowski C,. U.K. drug pricing scheme to allow generic substitution, promote innovation, 2008. Available at: http://tinyurl.com/359hqal (cited June 17, 2009).
22. Duh MS, Paradis PE, Latremouille-Viau D, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009; 72: 2122.
23. Meredith P,. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003; 25: 2875.
24. Johnston A,. Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. Curr Med Res Opin 2010; 26: 871.
25. Dowell JS, Snadden D, Dunbar JA,. Changing to generic formulary: how one fundholding practice reduced prescribing costs. BMJ 1995; 310: 505.
26. Melchior J,. Therapeutic drug substitution raises consumer concerns. Health Care News, 2009. Available at: http://tinyurl.com/6btfbaa(cited March 27, 2011).
27. Decollogny A, Eggli Y, Halfon P, Lufkin TM,. Determinants of generic drug substitution in Switzerland. BMC Health Serv Res 2011; 11: 17.
28. Gossell-Williams M,. Generic substitutions: a 2005 survey of the acceptance and perceptions of physicians in Jamaica. West Indian Med J 2007; 56: 458.
29. Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ,. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav 2008; 13: 693.
30. Meredith PA,. Generic drugs: therapeutic equivalence. Drug Saf 1996; 15: 233.
31. Helderman JH, Kang N, Legorreta AP, Chen JY,. Healthcare costs in renal transplant recipients using branded versus generic ciclosporin. Appl Health Econ Health Policy 2010; 8: 61.
32. Kingma I, Ludwin D, Dandavino R, et al. Economic analysis of Neoral in de novo renal transplant patients in Canada. Clin Transplant 1997; 11: 42.
33. Signorovitch J, Zhang J, Wu EQ, et al. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. Curr Med Res Opin 2010; 26: 849.
34. Colaizzi JL, Lowenthal DT,. Critical therapeutic categories: a contraindication to generic substitution? Clin Ther 1986; 8: 370.
35. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS,. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008; 71: 525.
36. Richton-Hewett S, Foster E, Apstein CS,. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med 1988; 148: 806.
37. Hellstrom J, Rudholm N,. Side effects of generic competition? Eur J Health Econ 2004; 5: 203.
38. Kovarik JM, Noe A, Wang Y, Mueller I, DeNucci G, Schmouder RL,. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus. Eur J Clin Pharmacol 2006; 62: 361.
39. Qazi YA, Forrest A, Tornatore K, Venuto RC,. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant 2006; 20: 313.
40. Roza A, Tomlanovich S, Merion R, et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation 2002; 74: 1013.
41. Hibberd AD, Trevillian PR, Roger SD, et al. Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. Transplantation 2006; 81: 711.
42. Taber DJ, Baillie GM, Ashcraft EE, et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation 2005; 80: 1633.
43. Food and Drug Administration (FDA). Approved drug products with therapeutic equivalence evaluations, 2009. Available at: (cited February 1, 2010).
44. Gottlieb S, One in three doctors don't tell patients about services they can't have. BMJ 2003; 327: 123. Available at: http://tinyurl.com/6j2t2mo (cited February 3, 2011).
45. Sheldon T,. Dutch insurance company will pay doctors to prescribe cheap drugs. BMJ 2006; 332: 254. Available at: http://tinyurl.com/6knx7aq(cited March 27, 2011).
46. Goldsmith D, Duerden M,. Statins: to switch or not to switch? Prescriber 2008; 19: 35.
47. Moon JC, Bogle RG,. Switching statins. BMJ 2006; 332: 1344.